Jennison Associates LLC Has $109.14 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Jennison Associates LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 500.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 889,187 shares of the biopharmaceutical company’s stock after buying an additional 741,044 shares during the quarter. Jennison Associates LLC’s holdings in Gilead Sciences were worth $109,139,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Corundum Trust Company INC acquired a new position in Gilead Sciences during the third quarter valued at approximately $26,000. Ares Financial Consulting LLC bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $28,000. Financial Consulate Inc. raised its stake in Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 109 shares during the period. MTM Investment Management LLC raised its stake in Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 176 shares during the period. Finally, BOCHK Asset Management Ltd bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $31,000. 83.67% of the stock is owned by institutional investors and hedge funds.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: FDA granted priority review for Gilead’s once‑daily bictegravir + lenacapavir (BIC/LEN) NDA with an August PDUFA date — this speeds potential U.S. commercialization and reduces regulatory timing risk if approved. FDA Grants Priority Review for BIC/LEN
• Positive Sentiment: Morgan Stanley bumped its price target to $175 and kept an overweight rating — a high‑profile analyst upgrade that can attract institutional interest and support further upside. Morgan Stanley Raises PT to $175
• Positive Sentiment: Gilead completed the Arcellx acquisition (~$7.8B), adding the anito‑cel cell therapy to its oncology pipeline — expands long‑term growth optionality beyond antivirals. Gilead Completes Arcellx Acquisition
• Positive Sentiment: Technical analysts point to a long‑term breakout retest (an 11‑year cup base) implying ~35% upside if it holds — this can trigger momentum/quant buying. Gilead Crosses Critical Breakout Level
• Neutral Sentiment: Wall Street still tilted bullish overall (many buy/overweight ratings; analysts expect earnings growth) — supportive backdrop but consensus already prices some upside. Wall Street Outlook on Gilead
• Neutral Sentiment: Gilead is due to report earnings next week with street models calling for growth — an earnings beat could extend the rally, a miss could reverse gains. Earnings Preview: Street Expects Growth
• Neutral Sentiment: Small analyst estimate tweaks and sector ETF flow commentary may drive short‑term volatility but are not company‑specific catalysts. Sector Context & ETF Flows
• Negative Sentiment: CEO Daniel O’Day sold 10,000 shares under a pre‑arranged 10b5‑1 plan — insider selling can create near‑term headline pressure even if routine. SEC Form 4: O’Day Sale
• Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking more transparency on patent exclusivities — could raise governance/IP uncertainty and headline risk around future exclusivity revenue. AHF Shareholder Resolution on Patents

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the transaction, the insider owned 120,288 shares in the company, valued at approximately $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00. Following the transaction, the chief executive officer owned 613,912 shares in the company, valued at approximately $92,086,800. This trade represents a 15.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 178,640 shares of company stock worth $26,584,250. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $130.84 on Friday. The firm has a market cap of $162.40 billion, a P/E ratio of 19.33, a price-to-earnings-growth ratio of 1.70 and a beta of 0.39. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 1-year low of $95.29 and a 1-year high of $157.29. The business’s 50 day moving average is $140.49 and its 200-day moving average is $132.35.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date was Friday, March 13th. Gilead Sciences’s dividend payout ratio is 48.45%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on GILD. Cantor Fitzgerald dropped their price objective on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, April 10th. Daiwa Securities Group upped their price objective on Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Barclays began coverage on Gilead Sciences in a research note on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a research note on Monday, February 23rd. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $157.35.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.